Pomalidomide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1297 publications

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Journal: Future oncology (London, England)

Published: April 13, 2026

A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-Monothiopomalidomide.

A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-Monothiopomalidomide.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Journal: The American journal of managed care

Published: March 26, 2026

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Journal: Chemical & pharmaceutical bulletin

Published: March 18, 2026

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells.

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells.

Journal: bioRxiv : the preprint server for biology

Published: March 13, 2026

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Journal: Cancers

Published: February 25, 2026

Preliminary Anti-Melanoma Activity of a Chlorogenic Acid-Based PROTAC Targeting MDM4, a Candidate Protein Identified by Proteomics.

Preliminary Anti-Melanoma Activity of a Chlorogenic Acid-Based PROTAC Targeting MDM4, a Candidate Protein Identified by Proteomics.

Journal: Foods (Basel, Switzerland)

Published: February 11, 2026

Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis

Elranatamab treatment in a refractory multiple myeloma patient on maintenance hemodialysis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 01, 2026

Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment.

Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment.

Journal: American journal of hematology

Published: January 29, 2026

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Journal: European journal of haematology

Published: January 09, 2026

Characteristics Associated with Clinical Response to Pomalidomide in Hereditary Hemorrhagic Telangiectasia.

Characteristics Associated with Clinical Response to Pomalidomide in Hereditary Hemorrhagic Telangiectasia.

Journal: Blood advances

Published: December 23, 2025

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design.

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design.

Journal: ChemMedChem

Published: December 18, 2025

Showing 1-12 of 1,297

Last Updated: 04/28/2026